Reply

Hepatology. 2020 Jul;72(1):360-361. doi: 10.1002/hep.31084.

Authors

Yoshitaka Arase^{1

2}, Tatehiro Kagawa¹, Atsushi Tanaka³

Affiliations

¹ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
² Division of Gastroenterology and Hepatology, Tokai University Oiso Hospital, Oisomachi, Japan.
³ Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

No abstract available

Publication types

Letter
Comment

MeSH terms

Denosumab
Humans
Liver Diseases*
Osteoporosis*

Substances

Denosumab